Treatment Philosophy and Goals
Currently, no treatment has been proven to slow the progression of Parkinson's disease neurodegeneration (neuroprotection remains an unmet therapeutic goal). All approved treatments are symptomatic — they alleviate motor and some non-motor symptoms but do not halt the underlying alpha-synuclein pathology.
Treatment decisions are individualized based on age, symptom severity, predominant features, comorbidities, lifestyle, and patient preferences. General approach:
- Early PD (age <60, mild symptoms): MAO-B inhibitors or dopamine agonists to delay levodopa initiation (reducing dyskinesia risk)
- Early PD (age >65–70, significant disability): Levodopa/carbidopa first-line (most effective, better tolerated in older patients)
- Motor fluctuations: Add COMT inhibitors, MAO-B inhibitors, or dopamine agonists; consider extended-release formulations or device-aided therapy
- Advanced PD with refractory fluctuations: Deep brain stimulation (DBS), intestinal levodopa infusion (Duopa), subcutaneous therapies
MAO-B Inhibitors
Rasagiline (Azilect) Selegiline (Eldepryl) Safinamide (Xadago)
Mechanism: Monoamine oxidase type B (MAO-B) is the predominant enzyme responsible for intrasynaptic dopamine catabolism in the brain. MAO-B inhibitors irreversibly (rasagiline, selegiline) or reversibly (safinamide) block this enzyme, reducing dopamine breakdown and prolonging dopamine availability in striatal synapses. As monotherapy in early PD, MAO-B inhibitors provide modest symptomatic benefit. As adjunct to levodopa, they reduce wearing-off by extending the duration of each levodopa dose's effect.
Individual Drugs
- Rasagiline (Azilect): 1 mg once daily (monotherapy or adjunct). Selective, irreversible MAO-B inhibitor — more potent and convenient than selegiline. No amphetamine metabolites (unlike selegiline).
- Selegiline (Eldepryl): 5 mg twice daily (at breakfast and lunch to avoid insomnia). Irreversible MAO-B inhibitor; metabolized to l-amphetamine and l-methamphetamine — can cause insomnia, hallucinations, especially in elderly. Orally-disintegrating sublingual tablet (Zelapar) available (avoids first-pass amphetamine metabolite formation).
- Safinamide (Xadago): 50–100 mg once daily (adjunct only). Reversible, selective MAO-B inhibitor with additional anti-glutamatergic (sodium channel) properties. Reduces wearing-off with a possibly favorable dyskinesia profile vs. levodopa dose increases.
Drug Interactions — CRITICAL: MAO inhibitors combined with serotonergic drugs risk serotonin syndrome. Avoid combining with: SSRIs, SNRIs, TCAs, meperidine (demerol — risk of hyperthermia, seizures, death), tramadol, methadone, linezolid. Tyramine restriction (avoid aged cheese, cured meats, fermented foods) — less critical for MAO-B selective inhibitors at therapeutic doses, but caution advised.
Dopamine Agonists
Pramipexole (Mirapex) Ropinirole (Requip) Rotigotine (Neupro patch) Apomorphine (Apokyn)
Mechanism: Dopamine agonists directly stimulate dopamine receptors (primarily D2 and D3 subtypes) without requiring conversion to dopamine. They have longer half-lives than levodopa (8–12 hours for oral agonists vs. 1.5 hours for levodopa), providing more continuous dopaminergic stimulation and reducing the pulsatile receptor stimulation that contributes to dyskinesias. They are efficacious as monotherapy in early PD and as adjuncts in advanced disease.
Individual Drugs
- Pramipexole (Mirapex IR/ER): Non-ergot; D2/D3 agonist (higher D3 affinity). IR: 0.5–1.5 mg three times daily. ER: 1.5–4.5 mg once daily. Renally cleared — dose reduce in CKD.
- Ropinirole (Requip IR/XL): Non-ergot; D2/D3 agonist. IR: 1–8 mg three times daily. XL: up to 24 mg once daily. Hepatically metabolized (CYP1A2) — interaction with fluvoxamine, ciprofloxacin, smoking cessation.
- Rotigotine (Neupro transdermal): Non-ergot; D1/D2/D3 agonist. Applied daily as transdermal patch (2–16 mg/24h). Useful when oral medications are not tolerated or for providing continuous baseline coverage overnight.
- Apomorphine: Most potent dopamine agonist (D1/D2). Available as subcutaneous injection (Apokyn, 2–6 mg; onset 5–10 minutes) for rescue of sudden off episodes, or subcutaneous continuous infusion (Olanexidyl). Requires ondansetron pretreatment for nausea (avoid if prolonged QTc).
Adverse Effects — Impulse Control Disorders: Dopamine agonists cause impulse control disorders (ICDs) in 13–17% of patients — compulsive gambling, hypersexuality, compulsive shopping, binge eating. More common in younger males with prior risk-taking behavior and depression history. Monitor actively; reduce or discontinue agonist if ICDs emerge. Additional concerns: leg edema, hallucinations (more than levodopa), orthostatic hypotension, and somnolence/sleep attacks (counsel against driving).
COMT Inhibitors
Entacapone (Comtan) Opicapone (Ongentys) Tolcapone (Tasmar)
Mechanism: Catechol-O-methyltransferase (COMT) is a major enzyme catabolizing levodopa peripherally (converting it to 3-O-methyldopa, which competes with levodopa at LNAA transporters) and centrally (catabolizing dopamine). COMT inhibitors extend levodopa's plasma half-life by reducing its peripheral conversion, thereby smoothing levodopa plasma levels and reducing wearing-off. Entacapone acts exclusively peripherally (does not cross BBB); tolcapone inhibits both peripheral and central COMT. COMT inhibitors are used exclusively as adjuncts to levodopa (they have no benefit without levodopa).
Individual Drugs
- Entacapone (Comtan): 200 mg with each levodopa dose (up to 8 times/day). Short half-life — must be taken with every levodopa dose. Available in fixed combination with carbidopa/levodopa as Stalevo (carbidopa/levodopa/entacapone in one tablet). Most widely used COMT inhibitor.
- Opicapone (Ongentys): 50 mg once daily at bedtime. Longer-acting; once-daily dosing independent of levodopa timing. Better convenience and potentially better overnight off period control. FDA-approved 2020.
- Tolcapone (Tasmar): 100–200 mg three times daily. More potent central + peripheral COMT inhibition, but requires liver function monitoring due to rare fatal hepatotoxicity (3 deaths). Reserved for patients who fail other COMT inhibitors.
Adverse Effects: GI effects (nausea, diarrhea — orange-brown urine discoloration from catechol metabolites is harmless). Increased levodopa-related side effects (dyskinesias, hallucinations — may need to reduce levodopa dose by 10–30% when adding COMT inhibitor). Tolcapone: rare hepatotoxicity — requires LFT monitoring every 2–4 weeks for 6 months.
Amantadine — Antiviral with Dopaminergic Properties
Mechanism: Amantadine's mechanism in PD is multifactorial: (1) NMDA glutamate receptor antagonism (reduces corticostriatal glutamatergic hyperactivity); (2) stimulates dopamine release from presynaptic terminals; (3) inhibits dopamine reuptake; (4) modest anticholinergic effects. Its anti-dyskinesia effect is primarily attributed to NMDA antagonism — blocking the enhanced glutamatergic drive that underlies dyskinesia expression. Extended-release amantadine (Gocovri 274 mg ER) is FDA-approved specifically for levodopa-induced dyskinesias.
Dosing: Standard amantadine: 100 mg twice daily (renally adjusted). Gocovri ER: 274 mg once daily at bedtime (extended release causes peak levels in the early morning when dyskinesias typically emerge). Reduce dose in renal impairment — drug is renally cleared.
Adverse Effects: Livedo reticularis (mottled purple skin discoloration — harmless), ankle edema, constipation, dry mouth, urinary retention, confusion and hallucinations (especially in elderly — use cautiously in patients with cognitive impairment). Abrupt discontinuation can worsen parkinsonism severely — taper slowly.
Deep Brain Stimulation (DBS)
Deep brain stimulation is a surgical treatment in which implanted electrodes deliver continuous high-frequency electrical stimulation to target brain nuclei, modulating pathological oscillatory activity in basal ganglia circuits. DBS is not a cure and does not halt disease progression, but provides substantial motor benefit for appropriately selected patients.
Mechanism
High-frequency stimulation (130–180 Hz) of target structures inhibits pathological neuronal firing (particularly the excessive beta-band oscillations in the 13–30 Hz range characteristic of PD). The exact mechanism remains debated — may involve: axonal antidromic/orthodromic inhibition, synaptic depression, local GABA release, and network-level desynchronization.
Target Structures
| Target | Best For | Advantages | Limitations |
|---|
| Subthalamic Nucleus (STN) | Motor fluctuations, dyskinesias, tremor | Allows significant levodopa dose reduction (~50%); well-studied; most widely used target | Risk of cognitive/mood side effects; requires more careful programming |
| Globus Pallidus Internus (GPi) | Dyskinesias (especially if levodopa reduction not desired), tremor | Direct anti-dyskinesia effect; less cognitive impact; preferred in older/cognitively impaired | Levodopa dose remains the same; longer battery life needed |
| Ventral Intermediate Nucleus (Vim) of thalamus | Tremor-dominant PD | Very effective tremor suppression; historically first DBS target | Does not address bradykinesia/rigidity; falls from tremor suppression revealing balance problems |
Patient Selection
Ideal DBS candidates:
- Confirmed idiopathic PD (not atypical parkinsonism)
- Good levodopa response (predictive of DBS response, except tremor)
- Motor fluctuations or dyskinesias causing functional disability despite optimized medications
- No significant cognitive impairment (MoCA ≥24) or active psychiatric disorder
- Sufficient physical health for neurosurgery
- Realistic expectations after thorough counseling
What DBS does NOT treat well: Freezing of gait (especially midline symptoms), speech and swallowing, autonomic dysfunction, cognitive decline, postural instability — these require non-dopaminergic system involvement and are disease-progression dependent.
Efficacy
STN-DBS (vs. best medical therapy, EARLYSTIM trial): ~50% improvement in UPDRS motor score; "on" time without dyskinesia increased by 4.6 hours/day; significant quality of life improvement. DBS benefits persist for at least 10 years in most patients for tremor and rigidity, though axial symptoms and cognitive decline progress with disease.
Risks: Surgical: hemorrhage (~1%), infection, lead displacement. Stimulation-related: dysarthria, cognitive effects, depression, worsening of gait/balance (especially Vim target), weight gain. Patients cannot have MRI in most DBS systems (conditional MRI-compatibility in newer devices). Require regular follow-up for programming adjustments. Battery replacement every 3–5 years (or rechargeable batteries extend this).
Treatment Algorithm Summary
| Stage | First Approach | Adjunctive Options |
|---|
| Early PD, age <60, mild symptoms | MAO-B inhibitor (rasagiline 1 mg/d) or dopamine agonist | Delay levodopa to minimize dyskinesia risk |
| Early PD, age >65 or significant disability | Carbidopa/levodopa (lowest effective dose) | MAO-B inhibitor adjunct may reduce wearing-off |
| Wearing-off emerging | Add entacapone or opicapone; or switch to Rytary ER | Add dopamine agonist; consider rasagiline/safinamide |
| Troublesome dyskinesias | Reduce levodopa dose + add dopamine agonist or COMT inhibitor | Amantadine (Gocovri); consider DBS evaluation |
| Advanced PD, refractory fluctuations | DBS evaluation (if surgical candidate) | Duopa intestinal gel; Vyalev SC infusion; apomorphine pump |
| Tremor-dominant (drug-refractory) | Evaluate for DBS (STN or Vim) | Focused ultrasound thalamotomy (Vim) — non-invasive |
Stay Informed on Parkinson's Treatment
Subscribe for updates on new therapies, clinical trials, and treatment guidelines.